Stable Angina – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Stable Angina Market Outlook

Thelansis’s “Stable Angina Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stable Angina treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Stable Angina Overview

Stable angina, or typical angina or angina pectoris, is a symptom of myocardial ischemia, characterized by chest discomfort or anginal equivalent triggered by exertion and relieved at rest or with nitroglycerin. This symptom arises from a supply-demand mismatch, where myocardial oxygen demand momentarily surpasses supply, often manifesting symptoms. The primary cause of stable angina is coronary artery stenosis, most frequently experienced during or after exercise, particularly in individuals with atherosclerosis. This condition leads to inadequate blood and oxygen delivery to actively respiring myocardial tissue, causing ischemia without myocardial necrosis, reflected in mostly normal biomarkers in blood. However, cardiac troponin release can aid in risk assessment. Chronic stable angina, recurring at a fixed rate-pressure product, contrasts with unstable and variant angina. Variant angina, or Prinzmetal angina, stems from coronary artery vasospasm, potentially leading to infarction but typically managed with vasodilators. Unstable angina, occurring at rest or waking patients at night, signifies a critical warning of impending myocardial infarction, also known as preinfarction angina. Chronic stable angina worsening with reduced exercise intensity may also indicate instability. In managing chronic stable angina, antianginal therapy continuity is vital perioperatively, with β-blockers maintained until the operation, preferably using long-acting preparations like nadolol or atenolol. Intravenous administration, such as propranolol, metoprolol, or esmolol, may be necessary if oral intake is delayed postoperatively, with a prompt shift back to oral therapy. Patients on long-term calcium channel antagonist treatment often receive oral preparations preoperatively, switching to intravenous or topical nitrates if oral intake is delayed, with intravenous options limited to verapamil and diltiazem.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: